The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: A retrospective study Thrombosis Research, 05/31/2012

Borsiczky B et al. – The results indicated that both CB and CHS had an identical inhibitory effect on ADP induced platelet aggregation in patients with cardiovascular diseases. Moreover their efficiency showed no overall significant difference in the case of dual antiplatelet therapy with aspirin as well. However there might be an inter– and intraindividual variability between the two clopidogrel formulas.

• Data of 150 patients with previous CHS treatment were investigated.
• According to the documentations, the CHS therapy was shifted to CB.
• 94 patients of the selected population received dual antiplatelet therapy, clopidogrel and aspirin.
• The antiplatelet effects of CHS and CB were compared by ADP induced platelet aggregation measurements using light transmission aggregometry.

• Irrespective of the therapeutic combinations the performed statistical investigations failed to show significant difference (p=0.30) between the effect of CB (AGGmaxCB: 27.6±13.7%) or CHS (AGGmaxCHS: 29.0±15.3%) on the ADP induced platelet aggregation.
• Insignificant deviations were found in both forms of clopidogrel salts, either in the lack (AGGmaxCB : 32.5±14,2%; AGGmaxCHS: 34,0±16,1%; p=0,29) or in the presence of aspirin (AGGmaxCB: 24.7±12,5%; AGGmaxCHS: 26,0±14,1%; p=0,31).